



## NORTHWEST BIOTHERAPEUTICS

Northwest  
Biotherapeutics, Inc.

4800 Montgomery Lane  
Suite 800  
Bethesda, MD 20814

t (240) 497-9024  
f (240) 627-4121

[www.nwbio.com](http://www.nwbio.com)  
OTCBB: NWBO

### Media Contacts:

Les Goldman, 202-371-7700  
[lgoldman@nwbio.com](mailto:lgoldman@nwbio.com)

Tom Redington 203-222-7399  
[trredington@redingtoninc.com](mailto:trredington@redingtoninc.com)

Heather Ford, 410-598-8256  
[hford@nwbio.com](mailto:hford@nwbio.com)

### **NW BIO TO PRESENT TODAY AT THE ONEMEDFORUM SF 2012 CONFERENCE**

#### ***Fifth Annual Emerging Company Forum Being Held In San Francisco In Conjunction With The JP Morgan Annual Healthcare Conference***

BETHESDA, MD, January 10, 2012 -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it will be making a presentation today at 10:45 am (PST) in the Windsor Room of the Sir Francis Drake Hotel as part of the fifth annual OneMedForum SF 2012 Conference for emerging biotech companies held over 3 days this week in conjunction with the JP Morgan Annual Healthcare Conference. Over one thousand attendees are expected to be listening to presentations by up to 100 companies at the OneMedForum, which will be webcast live at [www.onemedplace.com](http://www.onemedplace.com).

NWBT's presentation will include information on its DCVax® immune therapies for cancer, its development programs in the US and Europe, and its GBM brain cancer clinical trial, including the 25 active sites now open and recruiting across the US. NWBT's presentation will also cover the Company's multiple product candidates for diverse cancers, the Company's pipeline of INDs cleared by the FDA for clinical trials in multiple cancers, and the clinical data from prior clinical trials.

#### **About Northwest Biotherapeutics**

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the US and Europe. The Company has a broad platform technology for dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer. For further information about clinical sites and about the Company, please visit the Company's web site at [www.nwbio.com](http://www.nwbio.com).

## **Disclaimer**

*Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax<sup>®</sup> and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “believes,” “intends,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company’s products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.*